Trial
NCT01980875
Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Phase IIITERMINATEDSAFETYConfidence: HIGH
Sponsor
Gilead Sciences
Collaborators
—
Condition
Chronic Lymphocytic Leukemia
Intervention
Idelalisib
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-11-19